<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03135184</url>
  </required_header>
  <id_info>
    <org_study_id>HALO-FH</org_study_id>
    <nct_id>NCT03135184</nct_id>
  </id_info>
  <brief_title>HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia</brief_title>
  <official_title>HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HDL Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedStar Heart and Vascular Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>HDL Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the effect on coronary atheroma of serial infusions of autologous selectively
      delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PDS-2™ System is intended to reduce coronary atheroma in patients with Homozygous
      Familial Hypercholesterolemia (HoFH). Subjects will receive serial infusions of autologous
      selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics' PDS-2
      System.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, unblinded, interventional study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in coronary atheroma</measure>
    <time_frame>2 months</time_frame>
    <description>Assessed by coronary imaging in study coronary artery segments following serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System as compared to baseline</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Homozygous Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>HDL Therapeutics PDS-2™ System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HDL Therapeutics PDS-2 System</intervention_name>
    <description>Delipidation of plasma HDL to reduce coronary atheroma</description>
    <arm_group_label>HDL Therapeutics PDS-2™ System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Clinical diagnosis of Homozygous Familial Hypercholesterolemia (HoFH) due to a defect
             in the LDL receptor, or the identification of a defect in apoB-100, or a gain of
             function of PCSK9, or a genetic defect resulting in the HoFH clinical phenotype

          -  No other condition that would preclude the subject from successfully completing the
             series of plasmapheresis visits in the investigator's opinion

          -  At least one (1) coronary artery study segment will be identified for each subject and
             all will remain constant throughout the study. The qualifying study segment(s) will
             have 20% to 40% stenosis.

        Key Exclusion Criteria:

          -  Planned change in current lipid lowering therapy

          -  Use of oral anticoagulants, unless the dose has been stable for 4 weeks

          -  LDL or plasma apheresis within 1 week prior to enrollment and through 8-week primary
             endpoint

          -  New York Heart Association (NYHA) class III or IV or last known left ventricular
             ejection fraction &lt; 30%

          -  Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI),
             coronary artery bypass graft (CABG) or stroke within 3 months of enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bryan Brewer, MD</last_name>
    <phone>202-877-0188</phone>
    <email>Bryan.Brewer@MedStar.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center (CSMC)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prediman K Shah, MD</last_name>
      <phone>310-423-3884</phone>
      <email>shahp@cshs.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2017</study_first_submitted>
  <study_first_submitted_qc>April 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2017</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coal Tar</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

